Logo image of CR

CRANE CO (CR) Stock Fundamental Analysis

NYSE:CR - US2244081046 - Common Stock

195.67 USD
+3.77 (+1.96%)
Last: 8/26/2025, 8:22:55 PM
195.67 USD
0 (0%)
After Hours: 8/26/2025, 8:22:55 PM
Fundamental Rating

6

Taking everything into account, CR scores 6 out of 10 in our fundamental rating. CR was compared to 127 industry peers in the Machinery industry. CR gets an excellent profitability rating and is at the same time showing great financial health properties. While showing a medium growth rate, CR is valued expensive at the moment. These ratings would make CR suitable for quality investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

In the past year CR was profitable.
CR had a positive operating cash flow in the past year.
CR had positive earnings in each of the past 5 years.
CR had a positive operating cash flow in 4 of the past 5 years.
CR Yearly Net Income VS EBIT VS OCF VS FCFCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

With an excellent Return On Assets value of 13.98%, CR belongs to the best of the industry, outperforming 91.34% of the companies in the same industry.
The Return On Equity of CR (18.65%) is better than 81.10% of its industry peers.
Looking at the Return On Invested Capital, with a value of 13.83%, CR belongs to the top of the industry, outperforming 81.10% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CR is in line with the industry average of 10.48%.
The last Return On Invested Capital (13.83%) for CR is above the 3 year average (9.11%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 13.98%
ROE 18.65%
ROIC 13.83%
ROA(3y)10.39%
ROA(5y)10.5%
ROE(3y)19.31%
ROE(5y)22.01%
ROIC(3y)9.11%
ROIC(5y)8.41%
CR Yearly ROA, ROE, ROICCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

The Profit Margin of CR (16.60%) is better than 89.76% of its industry peers.
In the last couple of years the Profit Margin of CR has grown nicely.
Looking at the Operating Margin, with a value of 17.64%, CR belongs to the top of the industry, outperforming 81.89% of the companies in the same industry.
In the last couple of years the Operating Margin of CR has grown nicely.
With a decent Gross Margin value of 42.62%, CR is doing good in the industry, outperforming 77.95% of the companies in the same industry.
CR's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 17.64%
PM (TTM) 16.6%
GM 42.62%
OM growth 3Y15.82%
OM growth 5Y3.47%
PM growth 3Y-13.15%
PM growth 5Y27.77%
GM growth 3Y6.84%
GM growth 5Y2.54%
CR Yearly Profit, Operating, Gross MarginsCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

8

2. Health

2.1 Basic Checks

CR has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
CR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CR has less shares outstanding
CR has a better debt/assets ratio than last year.
CR Yearly Shares OutstandingCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CR Yearly Total Debt VS Total AssetsCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

An Altman-Z score of 13.01 indicates that CR is not in any danger for bankruptcy at the moment.
CR has a better Altman-Z score (13.01) than 95.28% of its industry peers.
CR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.16
Altman-Z 13.01
ROIC/WACC1.39
WACC9.97%
CR Yearly LT Debt VS Equity VS FCFCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 2.93 indicates that CR has no problem at all paying its short term obligations.
CR's Current ratio of 2.93 is fine compared to the rest of the industry. CR outperforms 77.17% of its industry peers.
CR has a Quick Ratio of 1.98. This is a normal value and indicates that CR is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CR (1.98) is better than 76.38% of its industry peers.
Industry RankSector Rank
Current Ratio 2.93
Quick Ratio 1.98
CR Yearly Current Assets VS Current LiabilitesCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.82% over the past year.
CR shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -3.00% yearly.
CR shows a decrease in Revenue. In the last year, the revenue decreased by -4.07%.
The Revenue has been decreasing by -8.28% on average over the past years.
EPS 1Y (TTM)23.82%
EPS 3Y-8.02%
EPS 5Y-3%
EPS Q2Q%13.85%
Revenue 1Y (TTM)-4.07%
Revenue growth 3Y1.09%
Revenue growth 5Y-8.28%
Sales Q2Q%-0.69%

3.2 Future

CR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.28% yearly.
Based on estimates for the next years, CR will show a quite strong growth in Revenue. The Revenue will grow by 8.40% on average per year.
EPS Next Y15.19%
EPS Next 2Y13.6%
EPS Next 3Y14.19%
EPS Next 5Y13.28%
Revenue Next Year6.65%
Revenue Next 2Y8.7%
Revenue Next 3Y8.76%
Revenue Next 5Y8.4%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CR Yearly Revenue VS EstimatesCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
CR Yearly EPS VS EstimatesCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6 8

1

4. Valuation

4.1 Price/Earnings Ratio

CR is valuated quite expensively with a Price/Earnings ratio of 35.51.
CR's Price/Earnings ratio is a bit more expensive when compared to the industry. CR is more expensive than 65.35% of the companies in the same industry.
CR's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.08.
Based on the Price/Forward Earnings ratio of 29.39, the valuation of CR can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CR indicates a slightly more expensive valuation: CR is more expensive than 65.35% of the companies listed in the same industry.
CR is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.67, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 35.51
Fwd PE 29.39
CR Price Earnings VS Forward Price EarningsCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

CR's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. CR is more expensive than 70.87% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CR is valued a bit more expensive than the industry average as 63.78% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 38.06
EV/EBITDA 25.39
CR Per share dataCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CR has an outstanding profitability rating, which may justify a higher PE ratio.
CR's earnings are expected to grow with 14.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.34
PEG (5Y)N/A
EPS Next 2Y13.6%
EPS Next 3Y14.19%

3

5. Dividend

5.1 Amount

CR has a yearly dividend return of 0.47%, which is pretty low.
CR's Dividend Yield is comparable with the industry average which is at 1.87.
With a Dividend Yield of 0.47, CR pays less dividend than the S&P500 average, which is at 2.34.
Industry RankSector Rank
Dividend Yield 0.47%

5.2 History

The dividend of CR decreases each year by -12.19%.
CR has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-12.19%
Div Incr Years0
Div Non Decr Years0
CR Yearly Dividends per shareCR Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

14.18% of the earnings are spent on dividend by CR. This is a low number and sustainable payout ratio.
DP14.18%
EPS Next 2Y13.6%
EPS Next 3Y14.19%
CR Yearly Income VS Free CF VS DividendCR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M
CR Dividend Payout.CR Dividend Payout, showing the Payout Ratio.CR Dividend Payout.PayoutRetained Earnings

CRANE CO

NYSE:CR (8/26/2025, 8:22:55 PM)

After market: 195.67 0 (0%)

195.67

+3.77 (+1.96%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)10-28 2025-10-28/amc
Inst Owners76.1%
Inst Owner Change58.18%
Ins Owners0.27%
Ins Owner Change-0.15%
Market Cap11.26B
Analysts82.35
Price Target215.01 (9.88%)
Short Float %1.34%
Short Ratio2.17
Dividend
Industry RankSector Rank
Dividend Yield 0.47%
Yearly Dividend0.82
Dividend Growth(5Y)-12.19%
DP14.18%
Div Incr Years0
Div Non Decr Years0
Ex-Date08-29 2025-08-29 (0.23)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.54%
Min EPS beat(2)3.28%
Max EPS beat(2)7.79%
EPS beat(4)4
Avg EPS beat(4)3.22%
Min EPS beat(4)0.24%
Max EPS beat(4)7.79%
EPS beat(8)8
Avg EPS beat(8)5.17%
EPS beat(12)11
Avg EPS beat(12)8.83%
EPS beat(16)15
Avg EPS beat(16)9.67%
Revenue beat(2)0
Avg Revenue beat(2)-1.25%
Min Revenue beat(2)-1.29%
Max Revenue beat(2)-1.2%
Revenue beat(4)0
Avg Revenue beat(4)-1.51%
Min Revenue beat(4)-2.46%
Max Revenue beat(4)-1.07%
Revenue beat(8)2
Avg Revenue beat(8)-0.73%
Revenue beat(12)4
Avg Revenue beat(12)2.9%
Revenue beat(16)6
Avg Revenue beat(16)0.35%
PT rev (1m)8.35%
PT rev (3m)15.72%
EPS NQ rev (1m)5.44%
EPS NQ rev (3m)3.4%
EPS NY rev (1m)4.26%
EPS NY rev (3m)5.26%
Revenue NQ rev (1m)-0.91%
Revenue NQ rev (3m)-1.43%
Revenue NY rev (1m)0.3%
Revenue NY rev (3m)0.6%
Valuation
Industry RankSector Rank
PE 35.51
Fwd PE 29.39
P/S 5.31
P/FCF 38.06
P/OCF 32.52
P/B 5.97
P/tB 10.77
EV/EBITDA 25.39
EPS(TTM)5.51
EY2.82%
EPS(NY)6.66
Fwd EY3.4%
FCF(TTM)5.14
FCFY2.63%
OCF(TTM)6.02
OCFY3.08%
SpS36.83
BVpS32.78
TBVpS18.16
PEG (NY)2.34
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.98%
ROE 18.65%
ROCE 17.88%
ROIC 13.83%
ROICexc 16.44%
ROICexgc 31.5%
OM 17.64%
PM (TTM) 16.6%
GM 42.62%
FCFM 13.96%
ROA(3y)10.39%
ROA(5y)10.5%
ROE(3y)19.31%
ROE(5y)22.01%
ROIC(3y)9.11%
ROIC(5y)8.41%
ROICexc(3y)10.78%
ROICexc(5y)10.01%
ROICexgc(3y)18.74%
ROICexgc(5y)19.36%
ROCE(3y)12.01%
ROCE(5y)11.18%
ROICexcg growth 3Y10.29%
ROICexcg growth 5Y0.39%
ROICexc growth 3Y13.04%
ROICexc growth 5Y6.99%
OM growth 3Y15.82%
OM growth 5Y3.47%
PM growth 3Y-13.15%
PM growth 5Y27.77%
GM growth 3Y6.84%
GM growth 5Y2.54%
F-Score7
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.16
Debt/EBITDA 0
Cap/Depr 101%
Cap/Sales 2.38%
Interest Coverage 19.47
Cash Conversion 81.73%
Profit Quality 84.11%
Current Ratio 2.93
Quick Ratio 1.98
Altman-Z 13.01
F-Score7
WACC9.97%
ROIC/WACC1.39
Cap/Depr(3y)93.58%
Cap/Depr(5y)79.88%
Cap/Sales(3y)1.9%
Cap/Sales(5y)1.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.82%
EPS 3Y-8.02%
EPS 5Y-3%
EPS Q2Q%13.85%
EPS Next Y15.19%
EPS Next 2Y13.6%
EPS Next 3Y14.19%
EPS Next 5Y13.28%
Revenue 1Y (TTM)-4.07%
Revenue growth 3Y1.09%
Revenue growth 5Y-8.28%
Sales Q2Q%-0.69%
Revenue Next Year6.65%
Revenue Next 2Y8.7%
Revenue Next 3Y8.76%
Revenue Next 5Y8.4%
EBIT growth 1Y13.55%
EBIT growth 3Y17.08%
EBIT growth 5Y-5.09%
EBIT Next Year24.5%
EBIT Next 3Y18.16%
EBIT Next 5Y14.77%
FCF growth 1Y152.76%
FCF growth 3Y-20.47%
FCF growth 5Y-6.44%
OCF growth 1Y165.56%
OCF growth 3Y-18.53%
OCF growth 5Y-7.3%